Skip to main content
Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR07

Evaluation of a Decentralized Infusion Pharmacist in an Oncology Infusion Clinic of an Academic Medical Center

JHOP - March 2025 Vol 15 Special Feature - HOPA Abstracts
Sarah Castelo, PharmD, BCOP; Nick Hopkins, PharmD, BCSCP

Presenting Author: Sarah Castelo, PharmD, BCOP, Vanderbilt University Medical Center, Nashville, TN

Co-Author: Nick Hopkins, PharmD, BCSCP, Vanderbilt University Medical Center, Nashville, TN

BACKGROUND: Pharmacists trained in oncology oversee and manage the use of oncology medications from a core pharmacy within the oncology infusion center. There are limited data on the value of a decentralized infusion pharmacist in an oncology infusion center.

OBJECTIVES: To improve efficiency of infusion clinic workflow by integrating an oncology-trained infusion pharmacist with the nursing staff to assist with troubleshooting, problem-solving, and communication with the core pharmacy and the clinical pharmacy specialists. Also, to improve patient care by providing more direct access to a pharmacist.

METHODS: This quality improvement study was conducted at an oncology infusion center at Vanderbilt University Medical Center, Nashville, TN, an academic medical center. A pharmacist worked in the decentralized infusion pharmacist role during peak clinic hours when the operations of the pharmacy could be safely and efficiently managed without the pharmacist physically located inside the core pharmacy. The decentralized infusion pharmacist worked in the oncology infusion clinic, integrated with the nursing staff. Data collected included the number of bedside double-checks for chemotherapy conducted, the number of questions fielded from nursing and the core pharmacy, communication with clinical pharmacy specialists, and patient education. The authors conducted an online satisfaction questionnaire after the pilot program was complete.

RESULTS: A total of 1796 patient visits were completed on 20 separate days from January 2024 to August 2024, when decentralized infusion pharmacist coverage was provided. The most common tasks performed by the decentralized infusion pharmacist included fielding questions from nursing (n=209), bedside double-checks for chemotherapy (n=156), and fielding questions from the core pharmacy (n=86). Of the staff members who completed the satisfaction questionnaire, 60% of nurses reported feeling less busy with the integration of a decentralized infusion pharmacist; whereas 54% of pharmacists in the core pharmacy reported no significant difference in their workload.

DISCUSSION: Decentralization of pharmacy services includes moving the decision-making closer to users. By adapting departmental workflow, pharmacy services are better able to support nurses. There was continuous effort to refine processes to address nursing and pharmacy concerns.

CONCLUSIONS: The integration of a decentralized infusion pharmacist in the oncology infusion clinic improved accessibility to a pharmacist, improved clinic workflow for the nursing staff, and increased the ability to troubleshoot issues. Further studies are needed to fully evaluate the effects the decentralized infusion pharmacist role would have on patient-related outcomes.

  1. Baroody C, Sandler M, Hong C, et al. Evaluation of a decentralized investigational drug service pharmacist in a cancer clinical trial infusion unit. J Oncol Pharm Pract. 2024;30:1200-1206.
  2. Chacko R, Worsham T, Gass J. Assessment of nursing satisfaction with pharmacy services. Poster presented at: ASHP 2019; December 8-12, 2019.
  3. Mashni OK, Nazer LH, Khalil, HZ, et al. Impact of clinical pharmacy services on patient management in the chemotherapy infusion clinics: a 5-year study at a comprehensive cancer center. J Pharm Pract. 2022;35:686-690.
Related Items
Optimizing Iron Dextran Infusion Protocols to Enhance Efficiency and Patient Throughput in an Outpatient Infusion Center: A Process Improvement Initiative
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Characteristics and Dosing Patterns of US Patients Diagnosed With HR-Positive/HER2-Negative Early Breast Cancer Initiating Abemaciclib at a Lower Dose Than the Approved 150 mg Twice Daily
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Clinical Characteristics and Treatment Persistence in US Patients With HR-Positive/HER2-Negative, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Clinical Outcomes of 2-Dose Tandem Influenza Vaccination Strategy in Patients With Plasma Cell Dyscrasias
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Dexamethasone Versus Tocilizumab for Management of Cytokine Release Syndrome Related to Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluating the Impact of Interactive Ambulatory Care Discussions at an Oncology Center
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of Reduced Observation Times for Subcutaneous Administration of Daratumumab and Hyaluronidase in Patients With Multiple Myeloma
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Evaluation of Services Provided by Pharmacists in Addition to Accredited Patient Management Program Responsibilities in a Health-System Specialty Pharmacy
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Hematologic Oral Oncolytics: Adherence, Healthcare Cost, and Utilization
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts
Identifying Barriers to Expanded Access Program (EAP) Patient Enrollment in the Hematology/Oncology Community
JHOP - March 2025 Vol 15 Special Feature published on March 12, 2025 in HOPA Abstracts